GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

The asset in question is GSK’s 72.5% stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare, famous for the malted ... healthcare nutrition products in March this year.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

However, it is possible that GSK will win the case, but Moderna still has a future… especially if they find a way to develop mRNA products without GSK’s LNP technology. I also have to ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

In weakly acid conditions, lipid A can be hydrolyzed to obtain monophosphoryl lipid A (MPL® [GSK and other]), a compound which retains the adjuvant activity of lipid A with reduced toxicity.

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...